Please enable JavaScript.
Coggle requires JavaScript to display documents.
Želudac (Th (st IV (target th (HER (ToGA (cis+5FU/cap), HR 0.74, OS+2.7 mj…
Želudac
Th
OP
ekstendirana limfadenektomija, 4 studije
DIM Japan (Dutch, Italian,MRC)
-
-
postop KT
kemoth
-
CLASIC, CAPOX, 1000 pts, HR 0.66 za OS+
-
ITACA-S, 1000 pts, 5FU/LC vs FOLFIRIx4 -Doc/Cis, HR 0.98
-
postop KRT
KRT
McDonalds int 0116, 560 pts, 5FU/LC+RT vs obs, OS 35 vs 27 mj
-
studije
krt vs KT adj
ARTIST, DFS=, +LČ DFS u krt, kt-XPx6; XPx2KRT+XpaXPx2
-
CRITICS, 800 pts, ECC/EOCx3 preop-OP-ECC/EOC vs KT (cis tj+kape)+RT45Gy/25x, OS krivulje iste
-
-
-
CALGB 80101, ECF vs 5FU/LV plus RT, OS jednak
-
preop KT
Neoadjuvatna KT
ACORD 07, Francuska, HR 0.66 +OS
-
STO03, ECX+/- bev, više AE, OS isti
-
MAGIC, 500p, ECF 3x2, pCR0
-
FLOT 4 (FLOTx4 -op-FLOTx4), želudac, GEJ, 70pts, OS 35 vs 50 mj za FLOT-u, HR 0.77
novi klinci
HER
INOVATION, FLOT/FOLFOX +/- tras ili Tras+pert
-
PETRARKA, FLOT +/- tras/pert
-
-
-
-
st IV
kemoth
mono vs kombo
meta analiza, HR 0.83 OS+
-
studije
-
-
-
FAMTXvsELFvsCF, = rezultati
faza 2
FOLFIRI, FOLFOX vs ECF, = rezultati, <AE
-
-
2 linija
Korejska studija, Irnio vs Doce VS BSC, +OS
-
-
target th
HER
ToGA (cis+5FU/cap), HR 0.74, OS+2.7 mj
-
LOGIC (Ox+cap), OS +1.7 SSOS
-
TITAN, 2L, pakl, OS+2.1 SS
-
GATSBY, TDM1 vs taxani, nSS
-
VEGR, bev, AVAGAST, HR0.87, nSS
-
HGF (hepatocit faktor growth), rilo, RILOMET,neg te METAGASTRIC (FolFOX+Onartuzumab)
-
-
IT
pembro
KN059, pembro, 260 pts, RR 12%
-
-
-
-
-
Općenito
PHD
TCGA
4 podtipa
MEGS (C): MSI, EBV, GS, CIN
-
-
-
-
-